2024 Annual Meeting | C105 - Alzheimer's Disease
Program Materials Program Evaluations
07:00 AM - 07:05 AM MDT | Introduction |
Welcome and Introductions
Liliana A. Ramirez-Gomez, MD |
07:05 AM - 07:40 AM MDT | Speaker |
The Use of Biomarkers for the Diagnosis and Staging of Alzheimer’s Disease
Julio C. Rojas-Martinez, MD, PhD |
07:40 AM - 08:10 AM MDT | Speaker |
Emerging Therapies for the Treatment of Alzheimer’s Disease
Jeremy J. Pruzin, MD |
08:10 AM - 08:40 AM MDT | Speaker |
Implementation of Newly Approved Disease-modifying Therapies for Alzheimer’s Disease in Clinical Practice
Liliana A. Ramirez-Gomez, MD |
08:40 AM - 09:00 AM MDT | Discussion |
Questions & Answers
Julio C. Rojas-Martinez, MD, PhD, Liliana A. Ramirez-Gomez, MD, Jeremy J. Pruzin, MD |
Liliana A. Ramirez-Gomez, MD | The institution of Dr. Ramirez-Gomez has received research support from NIA-NIH. |
Jeremy J. Pruzin, MD | Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from Alzheimer's Association. The institution of Dr. Pruzin has received research support from NIA. |
Julio C. Rojas-Martinez, MD, PhD | The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. Dr. Rojas-Martinez has received research support from Roon, Healthcare. The institution of Dr. Rojas-Martinez has received research support from Amylyx. |